Chemotherapy / Oncology — Hematologic

ABVD Chemotherapy Regimen (doxorubicin / bleomycin / vinblastine / dacarbazine)

Multiple manufacturers (component drugs); regimen components by Pfizer and others · Combination Chemotherapy Regimen

FDA Approved Components individually FDA-approved; ABVD is a well-established clinical regimen Intravenous (IV) infusion — combination regimen Specialty Medication
ABVD Chemotherapy Regimen Components box with doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine vials

What is ABVD Chemotherapy Regimen? ABVD is a standard combination chemotherapy regimen for Hodgkin lymphoma consisting of four drugs: Adriamycin (doxorubicin), Bleomycin, Vinblastine, and Dacarbazine. It is one of the most commonly used first-line treatment regimens for classical Hodgkin lymphoma.

About ABVD Chemotherapy Regimen

Brand NameABVD Chemotherapy Regimen
Generic / INNdoxorubicin / bleomycin / vinblastine / dacarbazine
Drug ClassCombination Chemotherapy Regimen
ManufacturerMultiple manufacturers (component drugs); regimen components by Pfizer and others
AdministrationIntravenous (IV) infusion — combination regimen
FDA ApprovalComponents individually FDA-approved; ABVD is a well-established clinical regimen
📦 ABVD is a regimen — not a single product. Individual components are dispensed separately.

FDA-Approved Uses for ABVD Chemotherapy Regimen

Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.

  • Classical Hodgkin lymphoma (cHL) — first-line treatment
  • Advanced-stage Hodgkin lymphoma
  • Early-stage Hodgkin lymphoma (in combination with radiation in some protocols)
Biomarker Note: PET scan response assessment (interim and end-of-treatment) is standard in Hodgkin lymphoma management and guides decisions about de-escalation or escalation of therapy.

How Does ABVD Chemotherapy Regimen Work?

ABVD combines four agents with different mechanisms: Doxorubicin (anthracycline — DNA intercalation, topoisomerase II inhibition), Bleomycin (glycopeptide antibiotic — DNA strand breaks), Vinblastine (vinca alkaloid — microtubule inhibition, cell cycle arrest), and Dacarbazine (alkylating agent — DNA alkylation). Together they attack multiple pathways in cancer cell proliferation.

Dosage & Administration

Standard ABVD: administered on days 1 and 15 of each 28-day cycle, for 4–6 cycles depending on disease stage and response. Each component is dosed by the oncologist based on BSA. Pulmonary function must be monitored due to bleomycin toxicity risk.

⚠️ Important

Dosing is individualized by the prescribing clinician. Never adjust your dose without consulting your healthcare provider. This information is educational only and does not replace the official prescribing information.

Warnings, Precautions & Side Effects

General Warning

Bleomycin pulmonary toxicity (can be life-threatening — discontinue bleomycin if pulmonary symptoms develop). Doxorubicin cardiotoxicity (cumulative dose-dependent). Vinblastine neurotoxicity. Dacarbazine severe nausea/vomiting. Myelosuppression. Secondary malignancies (long-term risk). Embryo-fetal toxicity.

⛔ Serious Warnings & Precautions
  • Bleomycin pulmonary toxicity (potentially fatal)
  • Doxorubicin cardiomyopathy
  • Severe myelosuppression
  • Secondary malignancies (AML/MDS)
  • Embryo-fetal toxicity

Common Side Effects

  • Nausea and vomiting
  • Alopecia
  • Fatigue
  • Myelosuppression
  • Peripheral neuropathy
  • Fever
  • Infertility risk

This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.

Storage & Handling

Each component has separate storage requirements. Doxorubicin: refrigerate. Bleomycin: refrigerate. Vinblastine: refrigerate. Dacarbazine: store at room temperature, protect from light. Prepared IV admixtures should be used promptly per institutional policy.

BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.

Insurance Coverage, Prior Authorization & Patient Assistance

🛡️ Commercial Insurance

ABVD Chemotherapy Regimen is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.

✅ Prior Authorization

Prior authorization is required by virtually all insurance plans for ABVD Chemotherapy Regimen. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.

🏥 Medicare Coverage

Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.

🆓 Patient Assistance

Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.

Prior Authorization Patient Assistance Insurance & Savings Medication Costs

Frequently Asked Questions — ABVD Chemotherapy Regimen

ABVD stands for Adriamycin (doxorubicin), Bleomycin, Vinblastine, and Dacarbazine — the four chemotherapy drugs that make up this regimen.

ABVD is the standard first-line chemotherapy regimen for classical Hodgkin lymphoma. It is used in both early-stage and advanced-stage disease, often in combination with radiation therapy for early-stage patients.

Bleomycin-induced pulmonary toxicity is among the most serious risks. If a patient develops lung symptoms (shortness of breath, cough, fever), bleomycin is typically discontinued. Doxorubicin cardiotoxicity is another serious cumulative risk.

Standard treatment is 4–6 cycles (each cycle is 28 days, with treatment on days 1 and 15). The exact number depends on disease stage, response to treatment (measured by PET scan), and institutional protocols.

ABVD components are covered under Medicare Part B (as IV chemotherapy administered in a clinical setting) and most commercial insurance plans when medically indicated and prior authorized. BiologicHealthPlus can assist with prior authorization.

Related Medications

Keytruda (pembrolizumab — relapsed/refractory HL)  ·  Adcetris (brentuximab vedotin)  ·  BrECADD regimen  ·  BEACOPP regimen

Related Conditions

Hodgkin lymphoma  ·  Classical Hodgkin lymphoma (cHL)  ·  Lymphoma

Comparisons

Oncology

Authoritative References

Medical Disclaimer: This page is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult your oncologist, hematologist, or licensed healthcare professional before making any treatment decisions. Last reviewed: August 2026 by the BiologicHealthPlus Clinical Team.